Recombinant interleukin-1 receptor antagonist protein prevents sensitization and intestinal anaphylaxis in guinea pigs.
Recombinant interleukin-1 receptor antagonist protein (rlRAP, 0.5 mg/kg) administered intraperitoneally in guinea pigs one hour before primary and booster parenteral sensitization (1 ml) by cow milk, led to a reduced immunoglobulin E (IgE) production, as displayed by a passive cutaneous anaphylaxis test. rlRAP administered intraperitoneally in sensitized guinea pigs at 0.5 mg/kg 10 min before challenge administration (beta-lactoglobulin, 100 mg per os), also prevents the colonic motor and secretory changes induced by intestinal anaphylaxis. These results suggest the involvement of interleukin-1 in food allergy and evidence a double protective role for rlRAP in food hypersensitivity.
Theodorou
V
V
Department of Pharmacology, INRA, Toulouse, France.
Fioramonti
J
J
Bueno
L
L
D000707:Anaphylaxis / Q000276:immunology / Q000517:prevention & control*; D000818:Animals; D000941:Antigens / Q000276:immunology / Q000494:pharmacology; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D005772:Gastrointestinal Transit / Q000187:drug effects / Q000502:physiology; D006168:Guinea Pigs; D007114:Immunization; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000627:therapeutic use; D007410:Intestinal Diseases / Q000276:immunology / Q000517:prevention & control*; D007782:Lactoglobulins / Q000009:adverse effects; D008297:Male; D016269:Milk Hypersensitivity / Q000276:immunology / Q000517:prevention & control; D009043:Motor Activity / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D012795:Sialoglycoproteins / Q000627:therapeutic use*
D000941:Antigens; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D007782:Lactoglobulins; D011994:Recombinant Proteins; D012795:Sialoglycoproteins